171 related articles for article (PubMed ID: 23841097)
21. IFN-α confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/W F1 mice.
Liu Z; Bethunaickan R; Huang W; Ramanujam M; Madaio MP; Davidson A
J Immunol; 2011 Aug; 187(3):1506-13. PubMed ID: 21705616
[TBL] [Abstract][Full Text] [Related]
22. Vaccination with autoreactive CD4(+)Th1 clones in lupus-prone MRL/Mp-Fas(lpr/lpr) mice.
Fujii T; Okada M; Fujita Y; Sato T; Tanaka M; Usui T; Umehara H; Mimori T
J Autoimmun; 2009 Sep; 33(2):125-34. PubMed ID: 19596182
[TBL] [Abstract][Full Text] [Related]
23. Pim-1 as a Therapeutic Target in Lupus Nephritis.
Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
[TBL] [Abstract][Full Text] [Related]
24. Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
Keil A; Hall SR; Körner M; Herrmann M; Schmid RA; Frese S
Arthritis Res Ther; 2016 Oct; 18(1):243. PubMed ID: 27770825
[TBL] [Abstract][Full Text] [Related]
25. Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice.
Pérez de Lema G; Maier H; Franz TJ; Escribese M; Chilla S; Segerer S; Camarasa N; Schmid H; Banas B; Kalaydjiev S; Busch DH; Pfeffer K; Mampaso F; Schlöndorff D; Luckow B
J Am Soc Nephrol; 2005 Dec; 16(12):3592-601. PubMed ID: 16267157
[TBL] [Abstract][Full Text] [Related]
26. Deletion of receptor for advanced glycation end products exacerbates lymphoproliferative syndrome and lupus nephritis in B6-MRL Fas lpr/j mice.
Goury A; Meghraoui-Kheddar A; Belmokhtar K; Vuiblet V; Ortillon J; Jaisson S; Devy J; Le Naour R; Tabary T; Cohen JH; Schmidt AM; Rieu P; Touré F
J Immunol; 2015 Apr; 194(8):3612-22. PubMed ID: 25762779
[TBL] [Abstract][Full Text] [Related]
27. Amelioration of human lupus-like phenotypes in MRL/lpr mice by overexpression of interleukin 27 receptor alpha (WSX-1).
Sugiyama N; Nakashima H; Yoshimura T; Sadanaga A; Shimizu S; Masutani K; Igawa T; Akahoshi M; Miyake K; Takeda A; Yoshimura A; Hamano S; Yoshida H
Ann Rheum Dis; 2008 Oct; 67(10):1461-7. PubMed ID: 18094002
[TBL] [Abstract][Full Text] [Related]
28. Monoclonal antibody therapy that targets phospholipid-binding protein delays lupus activity in MRL/lpr mice.
Mihaylova N; Bradyanova S; Chipinski P; Chausheva S; Kyurkchiev D; Tchorbanov AI
Scand J Immunol; 2020 Sep; 92(3):e12915. PubMed ID: 32533866
[TBL] [Abstract][Full Text] [Related]
29. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.
Dai H; He F; Tsokos GC; Kyttaris VC
J Immunol; 2017 Aug; 199(3):903-910. PubMed ID: 28646040
[TBL] [Abstract][Full Text] [Related]
30. [Molecular targets and their regulation in systemic lupus erythematosus and lupus nephritis].
Takasaki Y
Nihon Jinzo Gakkai Shi; 2012; 54(5):598-602. PubMed ID: 22991839
[No Abstract] [Full Text] [Related]
31. The central and multiple roles of B cells in lupus pathogenesis.
Chan OT; Madaio MP; Shlomchik MJ
Immunol Rev; 1999 Jun; 169():107-21. PubMed ID: 10450512
[TBL] [Abstract][Full Text] [Related]
32. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
[TBL] [Abstract][Full Text] [Related]
33. High titer anti-basement membrane antibodies in a subset of patients with pediatric systemic lupus erythematosus.
Orjuela A; Suwanichkul A; Canter D; Minard CG; Devaraj S; Hicks MJ; Muscal E; Wenderfer SE
Am J Nephrol; 2015; 41(3):241-7. PubMed ID: 25926050
[TBL] [Abstract][Full Text] [Related]
34. Mdm2 promotes systemic lupus erythematosus and lupus nephritis.
Allam R; Sayyed SG; Kulkarni OP; Lichtnekert J; Anders HJ
J Am Soc Nephrol; 2011 Nov; 22(11):2016-27. PubMed ID: 21949095
[TBL] [Abstract][Full Text] [Related]
35. The role of IL-23/IL-17 axis in lupus nephritis.
Zhang Z; Kyttaris VC; Tsokos GC
J Immunol; 2009 Sep; 183(5):3160-9. PubMed ID: 19657089
[TBL] [Abstract][Full Text] [Related]
36. Micelle-Forming Dexamethasone Prodrug Attenuates Nephritis in Lupus-Prone Mice without Apparent Glucocorticoid Side Effects.
Jia Z; Wang X; Wei X; Zhao G; Foster KW; Qiu F; Gao Y; Yuan F; Yu F; Thiele GM; Bronich TK; O'Dell JR; Wang D
ACS Nano; 2018 Aug; 12(8):7663-7681. PubMed ID: 29965725
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic effects of the artemisinin analog SM934 on lupus-prone MRL/lpr mice via inhibition of TLR-triggered B-cell activation and plasma cell formation.
Wu Y; He S; Bai B; Zhang L; Xue L; Lin Z; Yang X; Zhu F; He P; Tang W; Zuo J
Cell Mol Immunol; 2016 May; 13(3):379-90. PubMed ID: 25942599
[TBL] [Abstract][Full Text] [Related]
38. Murine lupus in the absence of alpha beta T cells.
Peng SL; Madaio MP; Hughes DP; Crispe IN; Owen MJ; Wen L; Hayday AC; Craft J
J Immunol; 1996 May; 156(10):4041-9. PubMed ID: 8621947
[TBL] [Abstract][Full Text] [Related]
39. IL-10 regulates murine lupus.
Yin Z; Bahtiyar G; Zhang N; Liu L; Zhu P; Robert ME; McNiff J; Madaio MP; Craft J
J Immunol; 2002 Aug; 169(4):2148-55. PubMed ID: 12165544
[TBL] [Abstract][Full Text] [Related]
40. Remission of systemic lupus erythematosus disease activity with regulatory cytokine interleukin (IL)-35 in Murphy Roths Large (MRL)/lpr mice.
Cai Z; Wong CK; Dong J; Chu M; Jiao D; Kam NW; Lam CW; Tam LS
Clin Exp Immunol; 2015 Aug; 181(2):253-66. PubMed ID: 25845911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
